Prognostic features in men who died of prostate cancer

Journal of Urology

Volumn 174, Issue 2, 2005, Pages 553-556

  Thompson, Kadee E ^a   Hernández, Javier ^a   Canby Hagino, Edith D ^a   Troyer, Dean ^a   Thompson, Ian M ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Mass screening; Mortality; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; BONE PAIN; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; COMORBIDITY; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; FOLLOW UP; FRACTURE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RACE; SYMPTOM; TREATMENT PLANNING; UNITED STATES; URETHRA OBSTRUCTION; WEIGHT REDUCTION;

EID: 22144446003     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000165184.72337.9d     Document Type: Article

References (13)

1. Stewart, S. L., King, J. B., Thompson, T. D., Friedman, C. and Wingo, P. A.: Cancer mortality surveillance-United States, 1990-2000. MMWR Surveill Summ, 53: 1, 2004
2. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A. et al: Cancer statistics, 2005. CA Cancer J Clin, 55: 10, 2005
3. Ross, P. L., Scardino, P. T. and Kattan, M. W.: A catalog of prostate cancer nomograms. J Urol, 165: 1562, 2001
4. Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L. et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med, 350: 2239, 2004
5. Roehl, K. A., Han, M., Ramos, C. G., Anterior, J. A. V. and Catalona, W. J.: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol, 172: 910, 2004
6. Chu, K. C., Tarons, R. E. and Freeman, H. P.: Trends in prostate cancer mortality among black men and white men in the United States. Cancer, 97: 1507, 2003
7. Kramer, B. S.: The science of early detection. Urol Oncol, 22:344, 2004
8. Thompson, I. M. and Zeidman, E. J.: Presentation and clinical course of patients ultimately succumbing to carcinoma of the prostate. Scand J Urol Nephrol, 25: 111, 1991
9. Eifel, P., Axelson, J. A., Costa, J., Crowley, J., Curran, W. J., Jr., Deshler, A. et al: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst, 93: 979, 2001
10. Ellis, R. J., Vertocnik, A., Sodee, B., Zhou, H., Kim, E., Young, B. et al: Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma. Brachytherapy, 2: 215, 2003
11. Jani, A. B., Basu, A., Abdalla, I., Connell, P. P., Krauz, L. and Vijayakumar, S.: Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer. Am J Clin Oncol, 26: 382, 2003
12. Sylvester, J. E., Blasko, J. C., Grimm, P. D., Meier, R. and Malmgren, J. A.: Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys, 57: 944, 2003
13. Balic, I., Graham, S. T., Troyer, D. A., Higgins, B. A., Pollock, B. H., Johnson-Pais, T. L. et al: Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. J Urol, 168: 2245, 2002